Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
Source: SeekingAlpha
2025-11-19 14:33:28 ET
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
0.31% G/L:
$27.52 Last:
223,426 Volume:
$27.76 Open:
AGIO Latest News
March 11, 2026 09:00:00 am
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
March 10, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
